Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for IQV.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 -214.00M
March 31, 2026 -433.00M
December 31, 2025 535.00M
September 30, 2025 -572.00M
June 30, 2025 145.00M
March 31, 2025 -258.00M
December 31, 2024 -375.00M
September 30, 2024 -137.00M
June 30, 2024 -260.00M
March 31, 2024 -106.00M
December 31, 2023 -420.00M
September 30, 2023 -144.00M
June 30, 2023 95.00M
March 31, 2023 87.00M
December 31, 2022 -193.00M
September 30, 2022 -251.00M
June 30, 2022 -29.00M
March 31, 2022 144.00M
December 31, 2021 -138.00M
September 30, 2021 -64.00M
June 30, 2021 -107.00M
March 31, 2021 -168.00M
December 31, 2020 -198.00M
September 30, 2020 -53.00M
June 30, 2020 -73.00M
Date Value
March 31, 2020 107.00M
December 31, 2019 -343.00M
September 30, 2019 39.00M
June 30, 2019 -200.00M
March 31, 2019 228.00M
December 31, 2018 -158.00M
September 30, 2018 -201.00M
June 30, 2018 -52.00M
March 31, 2018 -41.00M
December 31, 2017 45.00M
September 30, 2017 93.00M
June 30, 2017 -34.00M
March 31, 2017 -176.00M
December 31, 2016 -2.206B
September 30, 2016 24.40M
June 30, 2016 -97.55M
March 31, 2016 -4.99M
December 31, 2015 -270.97M
September 30, 2015 5.263M
June 30, 2015 -9.896M
March 31, 2015 26.36M
December 31, 2014 14.03M
September 30, 2014 9.709M
June 30, 2014 -157.09M
March 31, 2014 3.007M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Medpace Holdings, Inc. -288.34M
Charles River Laboratories International, Inc. -164.66M
Moderna, Inc. 14.00M
Fortrea Holdings, Inc. 0.00
OmniAb, Inc. 0.233M